CYP2C19 Polymorphisms in Indonesia: Comparison among Ethnicities and the Association with Clinical Outcomes

CYP2C19 polymorphisms are important factors for proton pump inhibitor-based therapy. We examined the genotypes and analyzed distribution among ethnicities clinical outcomes in Indonesia. employed polymerase chain reaction-restriction fragment length polymorphism method to determine evaluated inflammation severity with updated Sydney system. For CYP2C19*2, 46.4% were homozygous wild-type allele, 14.5% mutated 39.2% heterozygous allele. CYP2C19*3, 88.6% 2.4% 9.0% Overall, prevalence of rapid, intermediate, poor metabolizers Indonesia was 38.5, 41.6, 19.9%, respectively. In metabolizer group, frequency allele *2 (78.8%) higher than *3 (21.2%). The Papuan had a significantly likelihood possessing Balinese (OR 11.0; P = 0.002). lower compared rapid intermediate patients gastritis gastroesophageal reflux disease. Intermediate highest prevalence, followed by metabolizers. Dosage adjustment should therefore be considered when administering therapy